Navidea Biopharmaceuticals (NAVB +1.9%) gains after Burrill Institutional Research initiated the shares with a Market Outperform on valuation and a price target of $5 a share. The firm says the stock represents an undervalued opportunity with multiple near-term drivers that are likely to create shareholder value in 2013. Separately, Aegis Capital starts the stock with a Hold rating and a $3.00 price target.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs